InMed Pharmaceuticals (INM) Total Current Liabilities (2020 - 2026)
InMed Pharmaceuticals (INM) posted quarterly Total Current Liabilities of $2.2 million for Q1 2026, up 20.25% year-over-year from $1.8 million in Q1 2025, and up 49.41% quarter-over-quarter from $1.5 million in Q4 2025.
InMed Pharmaceuticals (INM) Total Current Liabilities (2020 - 2026) Analysis & Trends
InMed Pharmaceuticals' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $2.2 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 20.25% year-over-year to $2.2 million; the TTM figure through Mar 2026 stood at $2.2 million (up 20.25% YoY), while the FY2025 annual figure was $1.8 million, down 6.7% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $2.2 million, up from $1.5 million in the prior quarter.
- The five-year high for Total Current Liabilities was $4.1 million in Q1 2022, with the low at $1.3 million in Q3 2023.
- The 5-year median for Total Current Liabilities is $1.8 million (2025), against an average of $2.1 million.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities soared 139.49% in 2022, then tumbled 59.19% in 2023.
- InMed Pharmaceuticals' Total Current Liabilities stood at $2.4 million in 2022, then slumped by 30.0% to $1.7 million in 2023, then gained by 6.57% to $1.8 million in 2024, then decreased by 17.36% to $1.5 million in 2025, then surged by 49.41% to $2.2 million in 2026.
- Business Quant data shows INM's Total Current Liabilities at $2.2 million in Q1 2026, $1.5 million in Q4 2025, and $1.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - | -8.38 Bn |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn | 15.65 Bn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn | 2.06 Bn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn | 17.34 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn | 6.35 Bn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn | 874.50 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 1.85 Bn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - | 1.79 Bn |
| 10 | InMed Pharmaceuticals | 6.36 Mn | 1.11 Mn | - | 2.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.21 Mn |
| Dec 31, 2025 | 1.48 Mn |
| Sep 30, 2025 | 1.55 Mn |
| Jun 30, 2025 | 1.84 Mn |
| Mar 31, 2025 | 1.84 Mn |
| Dec 31, 2024 | 1.79 Mn |
| Sep 30, 2024 | 1.44 Mn |
| Jun 30, 2024 | 1.97 Mn |
| Mar 31, 2024 | 1.53 Mn |
| Dec 31, 2023 | 1.68 Mn |
| Sep 30, 2023 | 1.34 Mn |
| Jun 30, 2023 | 2.00 Mn |
| Mar 31, 2023 | 2.27 Mn |
| Dec 31, 2022 | 2.40 Mn |
| Sep 30, 2022 | 3.28 Mn |
| Jun 30, 2022 | 3.32 Mn |
| Mar 31, 2022 | 4.11 Mn |
| Dec 31, 2021 | 4.62 Mn |
| Sep 30, 2021 | 1.93 Mn |
| Jun 30, 2021 | 2.22 Mn |